Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Covington
Deloitte
Farmers Insurance
Cantor Fitzgerald

Generated: August 21, 2019

DrugPatentWatch Database Preview

Litigation Details for GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA (D. Del. 2014)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA
The small molecule drugs covered by the patents cited in this case are   Try a Free Trial and   Try a Free Trial .

Details for GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2016-04-12 110 Amended Infringement Contentions for U.S. Patent No. RE40,000 Against Defendant Glenmark Pharmaceuticals… 3 July 2014 1:14-cv-00877 830 Patent Plaintiff District Court, D. External link to document
2016-06-03 133 CHF, which issued as U.S. Patent No. 5,760,069 (the '"069 patent") entitled "Method… indirectly infringe U.S. Patent No. RE40,000 (the "'000 patent"). Presently before the…assignment, of the '000 patent, and GlaxoSmithKline LLC is the patent's exclusive licensee. (Id…, ex. B) Citation to the patent will simply be to the "'000 patent." … '000 Patent In June 1995, GSK and its research partner filed a patent application directed External link to document
2016-09-19 159 ., M.P.H. Regarding Infringement of U.S. Patent No. RE40,000 by Glenmark Pharmaceuticals, Inc. USA; (3… 3 July 2014 1:14-cv-00877 830 Patent Plaintiff District Court, D. External link to document
2017-02-17 251 for disputed terms in U.S. Patent No. RE40,000 (the "'000 Patent"); WHEREAS, on…29) The Court agrees with Judge Burke that the patent uses the term "maintenance dose" to draw…patient's tolerance ofthis amount). Rather, the patent consistently uses 1 This term…term appears in all claims of theĀ· '000 patent. …makes clear that the method claims Of the '000 patent cannot be practiced simply by "writing a External link to document
2017-05-02 299 CHF; the patent issued in June 1998 as U.S. Patent No. 5,760,069 (the "'069 patent"), entitled…069 patent, and on January 8, 2008, that patent reissued as the '000 patent. ('000 patent) In…United States Patent No. RE40,000 (the "Asserted Patent" or the '"000 patent"). Presently…60) If so, the patent claims a "new use" that is patentable; if not, the patent wrongly claims…the '000 patent claims were unknown in the prior art, the patent would claim a patentable new use of External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Merck
Queensland Health
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.